Ernexa’s ERNA-101 Achieves 100% Tumor Elimination in Preclinical Ovarian Models
Ernexa Therapeutics unveiled preclinical data showing its ERNA-101 candidate achieved complete tumor elimination and 100% long-term survival in ovarian cancer models when combined with PD-1 blockade. The company highlighted its off-the-shelf induced mesenchymal stem cell platform designed to address immunologically cold tumors and scale manufacturing for advanced cancer therapy.
1. Virtual Investor Segment
Ernexa Therapeutics released a Virtual Investor KOL Connect featuring Dr. Elena Ratner of Yale University, who detailed the significant challenges and unmet needs in ovarian cancer treatment. The segment emphasized limitations of current therapies and introduced ERNA-101’s potential to transform patient outcomes.
2. ERNA-101 Preclinical Efficacy
Recent preclinical studies demonstrated that ERNA-101, when combined with PD-1 blockade, produced complete tumor elimination and 100% long-term survival in ovarian cancer models. These findings underscore ERNA-101’s differentiated mechanism targeting immunologically cold tumors.
3. Off-the-Shelf iMSC Platform
Ernexa’s engineered allogeneic induced mesenchymal stem cell (iMSC) platform offers a scalable, off-the-shelf solution designed to overcome manufacturing challenges of autologous therapies. This approach aims to improve accessibility and consistency of cell therapies for advanced cancer patients.
4. Next Steps and Pipeline
Ernexa plans to advance ERNA-101 into clinical development, with ovarian cancer as its initial indication. The company’s broader pipeline includes ERNA-201 for autoimmune diseases and ongoing platform optimization to support future cell therapy candidates.